Cue Biopharma, Inc. (CUE)

NASDAQ: CUE · Real-Time Price · USD

25.39

-0.15 (-0.59%)

At close: Jun 26, 2026, 4:00 PM EDT

25.09

-0.30 (-1.18%)

After-hours: Jun 26, 2026, 5:11 PM EDT

-0.59% (1D)

Market Cap	102.72M
Revenue (ttm)	32.73M
Net Income (ttm)	-19.52M
Shares Out	4.05M
EPS (ttm)	-5.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,524
Open	25.76
Previous Close	25.54
Day's Range	24.60 - 26.75
52-Week Range	4.97 - 41.42
Beta	2.55
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About CUE

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inf... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 2, 2018

Employees 29

Stock Exchange NASDAQ

Ticker Symbol CUE

Website https://www.cuebiopharma.com

Full Company Profile

Financial Performance

In 2025, Cue Biopharma's revenue was $27.47 million, an increase of 195.75% compared to the previous year's $9.29 million. Losses were -$26.60 million, -34.60% less than in 2024.

Financial Statements

News

Cue Biopharma files to sell 551,724 shares of common stock for holders

16:07 EDT Cue Biopharma (CUE) files to sell 551,724 shares of common stock for holders

9 days ago - TheFly

Cue Biopharma Registration statement: Registration filing

Cue Biopharma filed a registration statement on June 18, 2026, providing details about a securities offering with the SEC.

10 days ago - Filings

Cue Biopharma registers to sell 4.09M shares of common stock for holders

This filing relates to the offer and sale from time to time by the selling stockholder of up to 4.09M shares of common stock. The company is not selling any…

24 days ago - TheFly

Cue Biopharma Transcript: Jefferies Global Healthcare Conference 2026

Precision immunoengineering drives a portfolio targeting allergic and autoimmune diseases, with CUE-221 and CUE-401 advancing through key clinical milestones. CUE-221 shows rapid, durable IgE suppression and is benchmarked against omalizumab, while CUE-401 targets regulatory T cell expansion for autoimmune therapy.

24 days ago - Transcripts

Cue Biopharma Slides: FY 2026

Cue Biopharma has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.

24 days ago - Filings

Cue Biopharma Registration statement: Registration filing

Cue Biopharma filed a registration statement on June 3, 2026, providing details about a securities offering with the SEC.

25 days ago - Filings

Cue Biopharma announces board transition, appoints two new directors

Cue Biopharma (CUE) announced the transition of its board as the company advances its strategic growth and development efforts. Effective May 29, four independent directors have resigned from the boar...

25 days ago - TheFly

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance an...

25 days ago - GlobeNewsWire

Cue Biopharma Transcript: EGM 2026

Stockholders approved the issuance of shares related to a licensing transaction, the 2026 Stock Incentive Plan, and the potential adjournment of the meeting if needed. Voting procedures and governance protocols were followed, with final results to be filed on Form 8-K.

27 days ago - Transcripts